Finally, with bioinformatics, in vitro, and in vivo data on the direct role of NCOA6 in the innate immune response and diseases, we suggest NCOA6 as a new therapeutic target for NLRP3-dependent diseases, including gouty arthritis and acute tubular necrosis. Here, NLRP3 is linked to gout.